info@strategicmarketresearch.com
26, Broadway, Suite 934, New York , 10004
United States Flag  US: +1-315-636-4233    United Kingdom Flag  UK: +44-162-237-0614    Indian Flag  IN: +91-826-083-6500
smrlogonew
  • Home
  • About
    • Why SMR
    • Research Methodology
    • Media Coverage
    • Join Our Team
  • Reports
    • Aerospace and Defense
    • Agriculture
    • Automotive
    • Chemicals and Materials
    • Consumer Goods
    • Energy and Power
    • Equipment and Machinery
    • Food and Beverages
    • Healthcare
    • Information and Communication Technology
    • Semiconductor and Electronics
    • Manufacturing and Construction
  • Our Practices
    • Syndicated Research
    • Consulting Services
    • Custom Research
    • Full-time Engagement Model
  • Insights
    • Press Release
    • Blog
  • Contact
Home » Press Releases » Recombinant Protein Market will be worth $3.93 billion by 2030

Recombinant Protein Market will be worth $3.93 billion by 2030


Published Date: Apr-2022 | Report Format:Electronic (PDF)

The report "Recombinant protein" Market by Product (Growth Factors (Blood and Tissue) and chemokines, Structural proteins, Kinase proteins, Human insulin, Regulatory proteins, Membrane proteins, Recombinant metabolic enzymes, Adhesion molecules and receptors, Immune response proteins, and Other recombinant proteins), Type (Biologics, Vaccines, Cell& gene therapy), & Region (North America, Europe, Asia Pacific, and Rest of the world)- Global Forecast to 2030. "The Global Recombinant Protein Market share was USD 1.5 billion in 2020. The market is expected to foster up to USD 3.93 billion by 2030, representing a CAGR of 10.12% throughout the forecasted period. 

 

To know more about the report, Click on the link :- https://www.strategicmarketresearch.com/market-report/recombinant-protein-market

 

KEY FACTORS THAT ARE CONTINUOUSLY AUGMENTING THE MARKET GROWTH

Some of the most notable factors that are driving the market's overall growth worldwide are the rise in government funding and the increase in R&D spending by pharmaceutical companies.

 

By Product, the Growth factors and chemokines segment held the highest share in 2020

Based on the Product, the recombinant protein market is segmented into Growth Factors (Blood and Tissue) and chemokines, Structural proteins, Kinase proteins, Human insulin, Regulatory proteins, Membrane proteins, Recombinant metabolic enzymes, Adhesion molecules and receptors, Immune response proteins, and Other recombinant proteins. 

 

Growth factors and chemokines have the largest market share. The application of growth factors and chemokines in many research areas such as chemotaxis, neurobiology, wound healing, immunology, transplantation, apoptosis, cancer, HIV/AIDS, COVID-19, cell culture, and stem cell research accounts for a major portion of the growth factors and chemokines market.

 

By Type, the 'Biologics' segment held the most significant share of the market in 2020

Based on the Type, The Biologics segment has the largest market. This is due to factors including the rising frequency and incidence of target illnesses, increased research and development, and a robust recombinant protein-based biologics development pipeline.

 

By Region, the "North America" accounted for the maximum share of the market in 2020

Based on Region, North America has the largest market share. And is the fastest-growing market for soft tissue repair. The rising prevalence of chronic and infectious illnesses, increasing R&D investment, expanding research activities, favourable government financing, and the presence of important companies in this area are all factors contributing to North America's big share of the worldwide market.

 

SOME OF THE NOTABLE PLAYERS ARE PREVAILING IN THE MARKET.

Some of the leading players in the Live-cell imaging Market include Thermo Fisher Scientific, Inc. (the US), R&D Systems (US), Abcam plc (UK), Merck KGaA (Germany), and Proteintech Group, Inc. (the US), Janssen-Cilag Pty Ltd., Aviva Systems Biology, Bio-Techne Corporation (US), Elpiscience BioPharma.

 

Recent Developments: -

  • In September 2021, Aviva Systems Biology, a pioneer in antibodies, immunoassay kits, and recombinant proteins for life science research announced the debut of their new Protein on Demand semi-custom recombinant protein portfolio for basic research and preclinical investigations.
  • In December 2020, Bio-Techne Corporation (US) and Elpiscience BioPharma collaborated. Elpiscience would have access to Bio-large Techne's product range of antibodies for use in the development of preclinical, clinical, and commercial biopharmaceuticals as part of this agreement, which is intended to produce anticancer treatments.
  • In February 2020, Merck KGaA (Germany) and Donghao Lansheng (Group) Co., Ltd. worked on a project (China). The goal of this partnership is to test a new import policy in China. It will make it easier for Merck to clear research items for biomedical innovation and analytical purposes via customs.

Choose License Type



$0
$0
$0
Buy Now
"Click to avail the latest sample copy of the report"
Request Sample
"Probe before placing the order"
Pre-Order Enquiry
"Let's optimize your ROI by furnishing the best price"
Request Discount
"Want to curate the report according to your business needs:"
Ask for Customization

Trust Online

  • paypal.png
  • wiretransfers

Follow Us

  • facebook
  • twitter
  • instagram
  • linkedin

Contact Us

  • US: (+1) 315-636-4233
  • UK: (+44) 1622-370-614
  • IN: (+91) 826-083-6500
  • info@strategicmarketresearch.com
  • Strategic Market Research
    26, Broadway Suite 934, New York , 10004

Quick Link

  • Why SMR
  • Research Methodology
  • Media Coverage
  • Join Our Team
  • Press Release
  • Blog

Customer Support

  • FAQs
  • Contact
  • Terms of Use
  • Privacy Policy
  • Disclaimer Policy
  • Return Policy
Copyright © 2022 Strategic Market Research All rights reserved